Therapeutic strategies targeting the Gas6/TAM axis, through anti-Gas6 or anti-Axl antibodies or small-molecule inhibitors, have been shown to modulate fibroblast-to-myofibroblast activation in IPF. Here, AXL is linked to idiopathic pulmonary fibrosis.